Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 257.46B +7.1% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 20.09 |
| Forward PE | 16.04 |
| Dividend | 9.80 (3.04%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 778,976 |
| Open | 322.00 |
| Previous Close | 320.70 |
| Day's Range | 317.40 - 323.50 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases,... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
The Zacks Analyst Blog Highlights Amazon.com, Bank of America, Roche, Oak Valley Bancorp and Ohio Valley Banc
Amazon, Bank of America and Roche are in focus as Zacks highlights growth drivers, expansion plans and product momentum across key businesses.
Roche (RHHBY) Commits to â¬600M Diagnostics Facility in Germany Amid Cost-Cutting Concerns
Roche (RHHBY) Commits to â¬600M Diagnostics Facility in Germany Amid Cost-Cutting Concerns
Roche sticks to German investment after Eli Lilly cuts
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
Top Stock Reports for Amazon, Bank of America & Roche
Amazon's AI push, sales outlook and diversified revenue streams stand out, while Bank of America and Roche navigate growth drivers and key risks.
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg.
NRIX Soars 38% on $2.3B Licensing Deal with Roche
NRIX Soars 38% on $2.3B Licensing Deal with Roche
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaboration
Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaboration
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg
(RTTNews) - Roche (RHHBY) announced it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NRIX). The two companies will co-develop and co-commercialise ...
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indica...
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose a...
Zealand touts promising tolerability data for obesity drug in mid-stage study
Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering its push to take on market leader...
Roche Develops Ebola PCR Test In Six Days Amid Bundibugyo Outbreak
(RTTNews) - Roche (RHHBY) has announced the rapid development of a Research Use Only (RUO) PCR test to detect the rare Ebola Bundibugyo virus, completing the assay within just six days of the genome s...
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
New Roche test targeting detection of Bundibugyo virus supports efforts to address critical need during ongoing outbreaks 1 Roche's unique outbreak response capabilities enabled rapid development of t...
Roche chairman likens US tariff policy to 'blackmail'
The chairman of Swiss pharmaceutical giant Roche hit out at U.S. tariff policies on Thursday, likening them to "blackmail", and said protectionism by the United States and China was the firm's bigge...
FDA Grants Priority Review For Roche's NDA For Giredestrant In Breast Cancer
(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, reported that its New Drug Application seeking approval for Giredestrant as an adjuvant treatment for patients with stage I-III ER+/HER- bre...
Roche Announces FDA's Filing Acceptance Under Priority Review For Giredestrant
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's New Drug Application under Priority Review for giredestrant, an investigational oral selective oestrogen receptor ...
FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--FDA accepts NDA for Genentech's giredestrant in ER+ early-stage breast cancer.
FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Basel, 02 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (US) Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under Prio...
Genentech Presents Updated Clinical Results Of Enicepatide And Petrelintide At ADA 2026
(RTTNews) - Genentech, a biotechnology company and member of the Roche group (RHHVF), announced that it will present new clinical data for Enicepatide and Petrelintide from its obesity portfolio to ad...
Louth GAA FL Division 2 Round-up: Walsh in sizzling form for Fechins as Roche sit top
Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions
Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association®...